Insulin therapy, delivered via subcutaneous (SC) injections or continuous subcutaneous insulin infusion (CSII) systems, remains indispensable, particularly in individuals with T1DM and those with progressive or inadequately controlled T2DM
Compounded Options: Local and national pharmacies continue to provide lower-cost alternatives, though recent semaglutide news highlights a major FDA crackdown on "mass-marketed" copycat versions to ensure patient safety
Storage expectations differ from some diabetes injections
By initiating treatment with a low dose and gradually increasing it, individuals can minimize side effects while still achieving substantial weight loss results
Scientific References Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics
Each dose increase brings a new wave of receptor activation, and with it, a new phase of appetite suppression, metabolic changes, and potential side effects